Pravastatin
Pravastatin is a statin, a medicine taken by mouth to lower LDL cholesterol. The FDA label says it is indicated to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 42463; UNII 3M8608UQ61. The label names the substance as pravastatin sodium, so UNII 3M8608UQ61 is the UNII of the salt form and is a broad match. MeSH descriptor D017035 is Pravastatin. Class: HMG-CoA Reductase Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Teva Pharmaceuticals USA, Inc. label for pravastatin sodium tablets (pravastatin sodium), application ANDA076056, effective 2024-01-01 in openFDA. This page records the label indication and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 4 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 4
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 2 |
| Phase 4 | 1 | 0 | 1 | 2 |
| All phases | 2 | 1 | 1 | 4 |
Conditions these trials study
- Dyslipidemia
- Diabetes mellitus
- High cholesterol (hypercholesterolemia)
- Hypertension (high blood pressure)
Sponsors with the most trials
- Kowa Research Institute, Inc.
- Sanofi
- Taipei Veterans General Hospital, Taiwan
- The George Washington University Biostatistics Center
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
3M8608UQ61
Claims and evidence
Context People for whom the US label of pravastatin lists an indication: adults with primary hyperlipidemia
- Recipient
- Adult
- Population
- Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol (LDL cholesterol) indication.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the passage read states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with primary hyperlipidemia
- Excluded
- None stated
The US label of pravastatin sodium tablets (pravastatin sodium), in the Teva Pharmaceuticals USA, Inc. version dated 2024-01-01 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.
Applies to Adult People for whom the US label of pravastatin lists an indication: adults with primary hyperlipidemia
- Certainty method
- Not assessed
- Limitations
- This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-07
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that gives the LDL-cholesterol indication.
- Retrieved
- Source effective date
- 2024-01-01
- Source state
- Current
- Version fingerprint
ed95365689d1e69f921584e7adab83c556914d79322fb72940fb9d38affe023f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20240101.
- Retrieved
- Source effective date
- 2024-01-01
- Source state
- Current
- Version fingerprint
ed95365689d1e69f921584e7adab83c556914d79322fb72940fb9d38affe023f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists lowering LDL cholesterol as an indication: Dyslipidemia
Applies to Adult People for whom the US label of pravastatin lists an indication: adults with primary hyperlipidemia
The US label of pravastatin sodium tablets (pravastatin sodium), in the Teva Pharmaceuticals USA, Inc. version dated 2024-01-01 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.Limitations. This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 4
Record details
- Record id
cardio:pravastatin- Content hash
0e00b08018a41e5fbf4133cc6170059151f023cad6aeba514448e871891ca632